Hansson, Oskar
Lehmann, Sylvain
Otto, Markus
Zetterberg, Henrik
Lewczuk, Piotr http://orcid.org/0000-0002-8101-6535
Funding for this research was provided by:
Fujirebio Europe (N/A)
Innovative Medicines Initiative Joint Undertaking (EMIF 115372)
Swedish Research Council (N/A)
Article History
First Online: 22 April 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: All authors have received consultation honoraria from Fujirebio Europe. PL has received honoraria for consultations and/or lectures from Fujirebio, IBL International, AJ Roboscreen and Roche. In the past 2 years, OH has received consultancy/speaker fees (paid to the institution) from Lilly and Roche. HZ has served on scientific advisory boards for Eli Lilly, Roche Diagnostics, Samumed, CogRx and Wave.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.